CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: November-25-14
Credit Expiration Date: November-25-15


David S. Siegel, MD, PhD (Moderator)
Chief, Myeloma Division
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, NJ

Sagar Lonial, MD
Professor and Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Emory University School of Medicine
Winship Cancer Institute
Atlanta, GA

Saad Z. Usmani, MD, FACP
Director of Plasma Cell Disorders Program
Director of Clinical Research in Hematologic Malignancies
Levine Cancer Institute/Carolinas Healthcare System
Clinical Associate Professor of Medicine
UNC-Chapel Hill School of Medicine
Charlotte, NC

Credit Hours

Physicians: 1 AMA PRA Category 1 CreditTM


Video Roundtable

Program Description

New evidence on optimal treatment approaches for patients with multiple myeloma (MM) is emerging at a rapid pace. Hematology and oncology clinicians are not fully prepared to incorporate emerging investigational therapies into treatment plans for patients with MM. Clinicians have the opportunity to improve outcomes in patients with MM by keeping abreast of evolving clinical practice guidelines to determine best approaches for each patient, including the optimal use of combination regimens and the use of tailored treatment approaches. This educational initiative is tailored to close gaps in knowledge, competence, and performance related to the treatment of patients with MM.

The goal of this activity is to increase the ability of hematology and oncology clinicians to incorporate the latest research and treatment recommendations for progressive or relapsed MM into their clinical practice, thus ensuring the best possible outcomes for each patient.

Program Developer/Facilitator


Target Audience

This activity is intended for the multiple myeloma care team, which includes oncologists, hematologist-oncologists, nurse practitioners, physician assistants, nurses, and other clinicians involved in the treatment of patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss recent updates to clinical practice guidelines reflecting changes in best practices for treatment of progressive or relapsed MM.
  2. Compare the efficacy and safety of guideline-recommended combination regimens for the treatment of progressive or relapsed MM.
  3. Risk stratify patients with progressive or relapsed MM.
  4. Develop individualized treatment approaches for patients with progressive or relapsed MM based on risk stratification.
  5. Describe toxicity profiles of MM therapies and considerations for individualizing treatment regimens based on these toxicities.
  6. Summarize current efficacy and safety data on emerging investigational therapies in late stages of development for the treatment of progressive or relapsed MM.


It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.

David S. Siegel, MD, PhD, has disclosed the following:
Consultant/Advisor: Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals
Speakers' Bureau: Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals

Sagar Lonial, MD, has disclosed the following:
Consultant/Advisor: Bristol-Myers Squibb, Celgene Corporation, Millennium Pharmaceuticals, Inc., Novartis, Onyx Pharmaceuticals, Sanofi

Saad Z. Usmani, MD, FACP, has disclosed the following:
Consultant/Advisor: Celgene Corporation, Novartis, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Sanofi
Research/Grant Support: Array BioPharma, Celgene Corporation, Janssen, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Pharmacyclics, Inc., Sanofi
Speakers' Bureau: Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals

Penn State faculty and staff involved in the development and review of this activity have nothing to disclose.

Anne Jacobson, MCM Education writer, has nothing to disclose.
Kathleen Hines, MCM Education editorial director, has nothing to disclose.

Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.

Credit Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit is awarded to participants who score 80% or better on the post-test.

The online activity will take approximately 60 minutes to complete.

For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or Please reference activity code G5618B-15-T.

Commercial Support Statements

This educational activity is supported by independent medical education grants from Millennium Pharmaceuticals, Inc. and Onyx Pharmaceuticals.


  1. There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; physicians should claim only those credits that reflect the time actually spent in the activity.
  2. Review the intended audience, learning objectives, and author disclosures.
  3. Study the educational content online.
  4. Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
  5. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Certificate Fee



The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Penn State College of Medicine, Millennium Pharmaceuticals, Inc., or Onyx Pharmaceuticals. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu